WO2005082398A3 - Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells - Google Patents
Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells Download PDFInfo
- Publication number
- WO2005082398A3 WO2005082398A3 PCT/US2005/005596 US2005005596W WO2005082398A3 WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3 US 2005005596 W US2005005596 W US 2005005596W WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- type
- hyperinsulinemia
- diabetes
- diagnosis
- protection against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05713932A EP1732582A2 (en) | 2004-02-26 | 2005-02-24 | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
AU2005216922A AU2005216922A1 (en) | 2004-02-26 | 2005-02-24 | Diagnosis of hyperinsulinemia and type II diabetes and protection against same based on genes differentially expressed in muscle cells |
CA002557181A CA2557181A1 (en) | 2004-02-26 | 2005-02-24 | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54751204P | 2004-02-26 | 2004-02-26 | |
US60/547,512 | 2004-02-26 | ||
US57934204P | 2004-06-15 | 2004-06-15 | |
US60/579,342 | 2004-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005082398A2 WO2005082398A2 (en) | 2005-09-09 |
WO2005082398A3 true WO2005082398A3 (en) | 2006-01-26 |
Family
ID=34915602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/005596 WO2005082398A2 (en) | 2004-02-26 | 2005-02-24 | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1732582A2 (en) |
AU (1) | AU2005216922A1 (en) |
CA (1) | CA2557181A1 (en) |
WO (1) | WO2005082398A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11976130B2 (en) | 2012-05-09 | 2024-05-07 | Astellas Pharma Inc. | Antibodies against claudin 18.2 useful in cancer diagnosis |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
DE102004024617A1 (en) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentially expressed in tumors gene products and their use |
CA2587790A1 (en) * | 2004-12-07 | 2006-06-15 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum |
GB0512401D0 (en) * | 2005-06-17 | 2005-07-27 | Randox Lab Ltd | Method |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
NZ594086A (en) * | 2009-02-27 | 2013-04-26 | Verva Pharmaceuticals Ltd | A drug identification protocol for type 2 diabetes based on gene expression signatures |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066787A2 (en) * | 1999-05-05 | 2000-11-09 | Ohio University | Growth hormone-regulatable liver genes and proteins, and uses thereof |
WO2004092419A2 (en) * | 2003-03-31 | 2004-10-28 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same (i) |
-
2005
- 2005-02-24 CA CA002557181A patent/CA2557181A1/en not_active Abandoned
- 2005-02-24 WO PCT/US2005/005596 patent/WO2005082398A2/en active Application Filing
- 2005-02-24 EP EP05713932A patent/EP1732582A2/en not_active Withdrawn
- 2005-02-24 AU AU2005216922A patent/AU2005216922A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066787A2 (en) * | 1999-05-05 | 2000-11-09 | Ohio University | Growth hormone-regulatable liver genes and proteins, and uses thereof |
WO2004092419A2 (en) * | 2003-03-31 | 2004-10-28 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same (i) |
Non-Patent Citations (9)
Title |
---|
"CLONTECH.PCR-Select differential screening kit. User Manual", CLONTECH, 10 September 2001 (2001-09-10), pages 1 - 35, XP002307356 * |
BERNAL-MIZRACHI E ET AL: "GENE EXPRESSION PROFILING IN ISLET BIOLOGY AND DIABETES RESEARCH", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON,, GB, vol. 19, no. 1, 2003, pages 32 - 42, XP008045358, ISSN: 1520-7552 * |
CALVO ROSA MARIA ET AL: "Immunohistochemical and morphometric studies of the fetal pancreas in diabetic pregnant rats. Effects of insulin administration", ANATOMICAL RECORD, vol. 251, no. 2, June 1998 (1998-06-01), pages 173 - 180, XP002332470, ISSN: 0003-276X * |
COROMINOLA H ET AL: "Identification of novel genes differentially expressed in omental fat of obese subjects and obese type 2 diabetic patients", DIABETES, NEW YORK, NY, US, vol. 50, no. 12, December 2001 (2001-12-01), pages 2822 - 2830, XP002293068, ISSN: 0012-1797 * |
GERLACH C ET AL: "PROLIFERATION-ASSOCIATED KI-67 PROTEIN IS A TARGET FOR AUTOANTIBODIES IN THE HUMAN AUTOIMMUNE DISEASE SYSTEMIC LUPUS ERYTHEMATOSUS", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 78, no. 1, January 1998 (1998-01-01), pages 129 - 130, XP002073106, ISSN: 0023-6837 * |
LIM H W ET AL: "Identification of differentially expressed mRNA during pancreas regeneration of rat by mRNA differential display", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 299, no. 5, 20 December 2002 (2002-12-20), pages 806 - 812, XP002324520, ISSN: 0006-291X * |
PIETILAEINEN T ET AL: "THE IMPORTANT PROGNOSTIC VALUE OF KI-67 EXPRESSION AS DETERMINED BY IMAGE ANALYSIS IN BREAST CANCER", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 122, no. 11, 1996, pages 687 - 692, XP008028143, ISSN: 0171-5216 * |
SONE H ET AL: "Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice.", DIABETOLOGIA. JAN 2005, vol. 48, no. 1, January 2005 (2005-01-01), pages 58 - 67, XP002332471, ISSN: 0012-186X * |
SURWIT R S ET AL: "Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and AJ mice", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 44, no. 5, May 1995 (1995-05-01), pages 645 - 651, XP004540280, ISSN: 0026-0495 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11976130B2 (en) | 2012-05-09 | 2024-05-07 | Astellas Pharma Inc. | Antibodies against claudin 18.2 useful in cancer diagnosis |
Also Published As
Publication number | Publication date |
---|---|
AU2005216922A1 (en) | 2005-09-09 |
CA2557181A1 (en) | 2005-09-09 |
WO2005082398A2 (en) | 2005-09-09 |
EP1732582A2 (en) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005082398A3 (en) | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells | |
WO2007067341A3 (en) | Compositions and methods for increasing insulin sensitivity | |
WO2004076639A8 (en) | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus | |
WO2004011611A3 (en) | Taci antibodies and uses thereof | |
WO2006020060A3 (en) | Iap binding compounds | |
WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
WO2006076691A8 (en) | Irta-2 antibodies and their uses | |
WO2004078938A3 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
WO2004044168A8 (en) | Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities | |
EP2020445A4 (en) | Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease | |
WO2007120156A3 (en) | Animal models of long qt syndrome and uses thereof | |
WO2005000335A3 (en) | Use of genes differentially expressed during aging of liver for treatment and diagnosis | |
WO2004081043A3 (en) | Baff mutants with at least one amino acid substitution and methods of their production | |
WO2008049098A3 (en) | ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1 | |
WO2006063009A3 (en) | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum | |
WO2007015926A3 (en) | Multiparameter flow cytometric cytometric cytotoxicity systems, methods, compositions and kits for evaluating the susceptibility of cancer | |
WO2005124358A3 (en) | Diagnosis and treatment of siglec-6 associated diseases | |
WO2006122971A3 (en) | Treatment of disease using an improved regulated expression system | |
WO2006086681A3 (en) | Methods of inhibiting smooth muscle cell migration and proliferation | |
CA2495529A1 (en) | Noonan syndrome gene | |
WO2007010258A3 (en) | Polymorphism in cysteine dioxygenase | |
WO2004044165A3 (en) | Lipid-associated proteins | |
WO2005052182A3 (en) | A method of analyzing plasma membrane protein content of cells | |
WO2007047335A3 (en) | Methods for use with baff antagonists | |
WO2004094673A3 (en) | Methods for monitoring drug activities in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2557181 Country of ref document: CA Ref document number: 2005216922 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005216922 Country of ref document: AU Date of ref document: 20050224 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005216922 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005713932 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005713932 Country of ref document: EP |